Tacrolimus Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is the crystalline monohydrate of the macrolide calcineurin inhibitor C44H69NO12·H2O, derived from fermentation with Streptomyces tsukubaensis and purified to compendial grade. The product is supplied in two model classes: an oral solid-dose grade for tablet, capsule, and granule operations, and an injectable grade for sterile liquid or lyophilized presentations. The oral grade is particle-size-controlled, while the injectable grade is differentiated by reduced bioburden, reduced endotoxin, and a solvent profile compatible with parenteral manufacture. Specification release follows the current USP-NF and Ph. Eur. monographs for Tacrolimus Monohydrate. The material is a white or almost white crystalline powder, practically insoluble in water and freely soluble in ethanol and methanol. The anhydrous form has the molecular formula C44H69NO12; the pharma-grade material is handled as the monohydrate to maintain crystalline stability during storage and processing.

Crystalline Monohydrate, Residual Solvents, and Compendial Limits

Identity is confirmed by infrared absorption spectrophotometry against a pharmacopeial reference standard and by specific rotation at 20 °C. Water content is determined by Karl Fischer titration according to Ph. Eur. 2.5.12 or USP <921> Method Ia; the theoretical water content of the monohydrate is approximately 2.2% w/w. Assay is performed by liquid chromatography and expressed on the anhydrous and solvent-free basis, with an acceptance range of 98.0–102.0% for the bulk drug substance. Residual solvents are controlled under Ph. Eur. 5.4 and USP <467> Option 2, with class 1 and class 2 solvent limits applied to the actual purification train. Related substances are quantified by the chromatographic procedures described in the monograph. Because the substance is fermentation-derived, the impurity profile may contain low levels of structurally related macrolides and epimers; individual and total impurities are reported on the Certificate of Analysis. The x-ray powder diffraction pattern must match the crystalline monohydrate reference diffractogram, and absence of a significant amorphous halo is controlled for oral-grade material intended for low-dose dry blending.

Fermentation-derived tacrolimus purification typically includes solvent extraction, chromatographic fractionation, and crystallization. The batch-to-batch impurity profile depends on the producing strain and downstream purification train. The oral grade may retain trace process solvents such as ethyl acetate or acetone, cleared below the concentration limits in Ph. Eur. 5.4 and USP <467> Option 2. The injectable grade is crystallized in a dedicated line with a final solvent exchange designed to reduce residual ethanol and acetone because the injectable vehicle may already contain dehydrated alcohol. For non-sterile oral solid-dose production, microbial limits are evaluated according to USP <61> and USP <62>, while the injectable grade is subject to bioburden control before terminal sterilizing filtration.

Controlling Amorphous Content and Particle Size Following Micronization

Micronization reduces primary particle size but introduces amorphous surface domains, electrostatic charge, and agglomeration. Particle-size distribution is measured by laser diffraction according to ISO 13320:2020, with dry dispersion used to limit solvent-induced aggregation. The D10, D50, and D90 limits are dossier-specific and are agreed between the API manufacturer and the drug product applicant; a typical micronized oral grade is controlled for a D90 below 20 µm, although published data for this specific configuration are limited for generic equivalence. The amorphous content is monitored by x-ray powder diffraction or modulated differential scanning calorimetry because amorphous tacrolimus can alter dissolution, stability, and blend adhesion. Milling energy, feed rate, and gas pressure are adjusted so that crystallinity remains within the approved release limit. Post-micronization conditioning at controlled relative humidity reduces triboelectric charge on stainless steel and plastic contact surfaces.

Oral solid-dose manufacture is dominated by low-dose content uniformity risk. Tablets and capsules are formulated at unit doses of 0.5 mg, 1 mg, and 5 mg, making the API weight fraction in common direct-compression blends less than 1.0 wt%. Micronized tacrolimus monohydrate is used to reduce segregation, but excessive micronization increases cohesion and poor flow. Processing at relative humidity above 60% is not recommended for dry blending because surface moisture increases particle cohesion and reduces flowability. Bulk density, tapped density, compressibility index, and Hausner ratio are measured according to USP <616> to establish whether direct compression or wet granulation is required.

What Limits Blend Uniformity in Low-Dose Tablet and Capsule Operations?

Geometric dilution with pre-sieved direct-compression lactose or mannitol is required before high-shear mixing or V-blending. The pre-blend is passed through a stainless steel screen with a nominal aperture below 500 µm to break agglomerates, then blended with a lubricant such as magnesium stearate. Content uniformity testing follows USP <905> for dosage units; because tacrolimus has a narrow therapeutic index, manufacturing is often operated with a tighter release limit than the compendial minimum acceptance value. Tablet compression on rotary presses with precompression capability limits lamination because the micronized API has low bulk density and high compressibility. Capsule filling on dosator or tamping-pin machines may require vacuum adjustment to prevent weight variation. If flowability of the final blend is insufficient, colloidal silicon dioxide is added at 0.5–1.0 wt% to improve powder flow without excessively increasing tablet friability. Dissolution testing of the finished product is performed according to USP <711> or Ph. Eur. 2.9.3 using surfactant-containing media because the drug is practically water-insoluble.

Wet granulation is used when direct compression cannot meet weight control on high-speed tablet presses. The granulation solvent can be purified water or ethanol; the drying step is operated at product temperature below 50 °C to limit amorphous conversion and surface dehydration of the monohydrate. Granule strength is balanced against tablet disintegration; excessive binder levels slow dissolution and complicate bioequivalence for a poorly water-soluble compound. Granulation end point is controlled by loss on drying and by x-ray powder diffraction checks for crystalline monohydrate retention. Aqueous granulation at high moisture content may produce an agglomerated, less uniform state; therefore, the granulation process is designed to minimize the residence time at elevated moisture and temperature.

When Oxygen, Sterile Filtration, and Endotoxin Burden Define Injectable Suitability

Tacrolimus injectable grade is not a separate chemical entity but a reduced-bioburden, reduced-endotoxin lot of the monohydrate. Release testing includes bacterial endotoxins by Ph. Eur. 2.6.14 or USP <85>; the limit is dose-based and derived from the maximum allowable endotoxin administration associated with the clinical infusion protocol. Bioburden control is performed before terminal sterilizing filtration; bulk solution is filtered through a validated 0.22 µm membrane. Filter compatibility must be verified because tacrolimus may adsorb to hydrophobic membranes at low concentration; polysorbate or polyoxyl 60 hydrogenated castor oil in the formulation reduces adsorption but introduces oxygen-sensitive micellar phases. Dissolved oxygen is purged with nitrogen before filling. Particulate matter in the final reconstituted solution is controlled by USP <788> or Ph. Eur. 2.9.19. Residual oxygen in the headspace is measured by a headspace analyzer, and light exposure is minimized because the solution can undergo photodegradation. The injectable grade is supplied with a reduced residual solvent inventory because the injectable vehicle itself contains dehydrated alcohol, and cumulative solvent exposure must remain within the approved label.

In a lyophilized injectable presentation, the tacrolimus solution is filled into glass vials, freeze-dried, and sealed under nitrogen. The API must have a low initial moisture content and low amorphous fraction to avoid collapse or excessive moisture in the lyo cake. Reconstitution time is tested with the approved diluent. The use of micronized injectable grade is generally avoided because particle size is not critical after complete dissolution, but undissolved particles can increase sterilizing filter load and block membrane pores. Filter integrity testing is performed by bubble point or forward-flow diffusion before release; the bubble point value is membrane-specific and is recorded in the batch record. Adsorptive loss to filtration media and tubing must be evaluated at low drug concentration because tacrolimus has a narrow therapeutic index and any loss can shift the delivered dose.

Differences from Cyclosporine, Sirolimus, and Non-Micronized Tacrolimus Batches

Tacrolimus differs from cyclosporine in both chemical structure and molecular target. Cyclosporine is a cyclic undecapeptide that binds to cyclophilin; tacrolimus is a macrolide that binds to FKBP12, and both inhibit calcineurin-mediated T-cell activation. The molecular difference influences formulation: cyclosporine is available as a microemulsion concentrate, while tacrolimus oral capsules use a solid dispersion or micronized crystalline API with a carrier. Compared with sirolimus, which inhibits mTOR after binding to FKBP12, tacrolimus acts earlier in the signaling cascade. For formulators, the practical differences among products are water solubility, dose size, degradation chemistry, and handling requirements. Tacrolimus is dosed at milligram levels, whereas cyclosporine is dosed at tens to hundreds of milligrams, so the content uniformity burden for tacrolimus is higher. Non-micronized tacrolimus monohydrate may be acceptable for research or compounding but is not appropriate for direct low-dose oral solid dosage forms; it requires milling or pre-dispersion before use.

Storage is at controlled room temperature in airtight, light-resistant containers. The bulk API is typically packed in a double polyethylene liner inside a sealed fiber drum. Re-test period is established by the manufacturer based on long-term and accelerated stability data under ICH storage conditions. Production-scale handling in dry powder form requires relative humidity control below 60% and grounding of stainless steel equipment to dissipate electrostatic charge. Batch-to-batch variance in particle size, water content, and residual solvents is verified before release for production. The material should not be exposed to strong acids or strong bases because the macrolide ring and hemiketal functionality are sensitive to pH extremes; forced degradation studies show hydrolysis products at low and high pH, and these degradation species are monitored by the related substances method.